Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Gastroenterology Neurology Rheumatology Diabetes / Metabolic Mental Health / Psychiatry Women's Health Dermatology Men's Health Rare Diseases
Clinical Trial ● Currently Recruiting Phase II NCT07260669

A Phase 2 Trial to Investigate Efficacy and Safety of Vipoglanstat in Women With Endometriosis

A Phase 2 Trial to Investigate Efficacy and Safety of Vipoglanstat in Women With Endometriosis — Recruiting • Phase II • Women's Health • NCT07260669.

📅 17 Apr 2026 ⏱ 1 min read
Currently Recruiting
This trial is actively seeking participants in the UK. Discuss eligibility with your patient before referring.
Status
Currently Recruiting
Phase
Phase II
NCT ID
NCT07260669
Start
2025-10-15
Completion
2027-06
ClinicaliQ Trial Snapshot
  • A Phase 2 Trial to Investigate Efficacy and Safety of Vipoglanstat in Women With Endometriosis — Recruiting • Phase II • Women's Health • NCT07260669.
  • A study testing whether vipoglanstat reduces pelvic pain in women with endometriosis, beyond pain linked to periods.

Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.

Use This Page For
  • Quick orientation before opening the registry record.
  • Checking recruitment status, phase and sponsor at a glance.
  • Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying

The main objective of the trial is to evaluate the efficacy of vipoglanstat on endometriosis-related non-menstrual pelvic pain (NMPP). Conditions: Endometriosis Interventions: Vipoglanstat, Placebo Lead Sponsor: Gesynta Pharma AB Planned Enrollment: 190 participants

Full Trial Details
View this trial on the source registry
Eligibility criteria, protocol, and results when available
View Trial ↗
Share: Twitter/X LinkedIn
Related

Related Clinical Intelligence

Guidelines, Drug Science, safety briefs and education connected to this trial area.

Clinical Brief
Valproate (Belvo, Convulex, Depakote, Dyzantil, Epilim, Epilim Chrono or Chronosphere, Episenta, Epival, and Syonell▼): new safety and educational materials to support regulatory measures in men and women under 55 years of age
Women's Health · MHRA · 22 Jan 2024
Valproate (Belvo, Convulex, Depakote, Dyzantil, Epilim, Epilim Chrono or Chronos...
View brief →
Guideline
Endometriosis: Diagnosis and Management (NICE NG73)
Women's Health · 27 Mar 2026
Suspect endometriosis in women presenting with chronic pelvic pain, dysmenorrhoea, or deep dyspareunia; refer to gynaecology if symptoms persist after adequate trial…
View guideline →
Clinical Brief
Women can wait years for an endometriosis diagnosis. New tech could change that
Women's Health · BBC Health · 30 Apr 2026
New scan technology can detect endometriosis lesions missed by conventional ultrasound and MRI, potentially reducing diagnostic delays that currently extend several years…
View brief →
Clinical Brief
Ultrasound delays putting pregnant women and cancer patients at risk, sonographers say
Oncology · BBC Health · 28 Mar 2026
Ultrasound service capacity is insufficient due to inadequate sonographer training, creating delays that compromise care for pregnant women and cancer patients requiring…
View brief →
CPD
MHRA Drug Safety: Valproate in Women of Childbearing Potential
Mental Health / Psychiatry · 1.0 CPD hour · 25 Mar 2026
Explain the fetal and developmental risks associated with valproate exposure in pregnancy. Apply MHRA Pregnancy Prevention Programme requirements, including annual specialist review,…
Complete CPD →
Clinical Brief
‘Doctors thought my endometriosis was IBS’
Women's Health · BBC Health · 08 Apr 2026
Endometriosis is frequently misdiagnosed as IBS, delaying diagnosis and treatment; clinical awareness of overlapping gastrointestinal symptoms is essential for timely identification. Patient…
View brief →